Reframing Inflammatory Bowel Disease as a Subset of Chronic Inflammatory Response Syndrome: The Role of Biotoxin-Induced Innate Immune Dysfunction

Author: Alli Manzella, CIRS-Literate FNTP, Environmental Health Specialist
Co-Founder, Root Cause for Crohn’s & Colitis (RCFCC)
Date: June 2025

Background: Inflammatory Bowel Disease (IBD) is traditionally framed as a chronic, idiopathic autoimmune disorder. Despite advancements in therapeutics, unmedicated remission remains elusive, suggesting an incomplete pathophysiologic model.

Objective: To synthesize clinical and molecular evidence supporting the concept that a subset of Inflammatory Bowel Disease reflects underlying innate immune dysregulation in HLA-susceptible individuals, often presenting within the clinical framework of Chronic Inflammatory Response Syndrome (CIRS) following environmental exposures. This is characterized by impaired immune regulation, loss of barrier integrity, disruption of mucosal immunity, and secondary microbiome destabilization.

Methods: Narrative review of PubMed-indexed literature (2000–2025) on IBD, innate immunity, CIRS biomarkers, and HLA DR/DQ genetics.

Search terms included: "inflammatory bowel disease” "innate immune dysfunction," "mycotoxin inflammasome," and "site specific immunomodulator." Mechanistic claims were cross-verified with primary literature and indexed studies (references sited).

Introduction

Chronic Inflammatory Response Syndrome (CIRS) is a multisystem, acquired illness characterized by impaired regulation of innate immune responses, often arising in genetically susceptible individuals following environmental biotoxin exposures. It is identified through a combination of symptom clusters, HLA-DR/DQ haplotyping, visual contrast sensitivity (VCS) testing, and a panel of immune and inflammatory biomarkers, including C4a, TGF-β1, and MSH.

Initially described in the context of mold illness and water-damaged building exposure, CIRS is increasingly recognized as a broader disorder of immune dysregulation affecting multiple organ systems, including mucosal, neurological, vascular, endocrine, gastrointestinal, and cutaneous (integumentary) systems.

Multisusceptible HLA haplotypes, particularly 4-3-53 and 11-3-52B, are associated with altered antigen presentation and impaired resolution signaling, predisposing approximately 25% of individuals to persistent immune dysfunction following environmental exposures. These same HLA-DR and DQ haplotypes have been identified at increased frequency in IBD cohorts, supporting a shared genetic and immunologic vulnerability.

Figure 1. Sample Report HLA-DR/DQ Haplotyping

Environmental Biotoxins as Drivers of Innate Immune Activation and Dysregulation

Environmental biotoxins, including mycotoxins, bacterial endotoxins, tick-borne pathogens, and immunogenic exposures such as vaccine antigens and adjuvants, are capable of initiating innate immune activation through pattern recognition pathways. These agents engage pattern recognition receptors (PRRs), including Toll-like receptors (TLR2, TLR4) and NOD-like receptors (NLRs), on epithelial and mucosal immune cells, triggering intracellular signaling cascades that result in the production of pro-inflammatory cytokines and chemokines.

Lipopolysaccharide (LPS), a component of Gram-negative bacterial cell walls, is a potent ligand for TLR4 and induces activation of NF-κB signaling, driving the release of TNF-α, IL-1β, and IL-6. Mycotoxins such as ochratoxin A and trichothecenes disrupt mitochondrial function, induce oxidative stress, and activate inflammasome pathways, including NLRP3, amplifying inflammatory signaling. Tick-borne pathogens and their associated antigens engage TLR2 and NLR pathways, contributing to persistent immune activation through antigen persistence and immune evasion mechanisms. In parallel, certain vaccine components, particularly adjuvants, are designed to activate innate immune receptors, including TLR and NLR pathways, to enhance antigen presentation and immune response.

In a healthy host, activation of these pathways is transient and followed by resolution, restoring immune homeostasis. However, in individuals carrying specific HLA-DR/DQ haplotypes, including 4-3-53 and 11-3-52B, repeated or sustained exposure to these stimuli may impair antigen presentation and resolution signaling. This results in prolonged activation of innate immune pathways without appropriate termination, driving a transition from acute, protective inflammation to a state of innate immune dysregulation (IID).

IID is characterized by persistent inflammatory signaling, impaired resolution capacity, altered immune tolerance, and progressive cellular exhaustion. Importantly, the inciting trigger is not always clearly identifiable. Rather, chronicity appears to arise from persistent or sequential exposures capable of engaging innate immune sensing pathways in a system that has lost the capacity to appropriately regulate and resolve these responses.

The following chart outlines key biotoxins known to breach barrier defenses and initiate the progression of immune injury:

Chart 1: Biotoxins Associated with Innate Immune Dysregulation

Chart 2: Endogenous Biotoxin Exposures (Secondary Amplifiers)

Innate Immune Dysregulation as a Driver of Chronicity and Systemic Disease

Once established, innate immune dysregulation fundamentally alters host defense mechanisms, creating a self-perpetuating cycle of inflammation and immune dysfunction. A defining feature of this state is the loss of the immune system’s ability to appropriately regulate, resolve, and compartmentalize immune responses, resulting in both persistent activation and functional impairment across multiple domains of innate immunity.

In this context, critical roles of innate immune function become compromised. These include impaired communication with the adaptive immune system, reduced immune surveillance, insufficient pathogen and biotoxin clearance, and failure of mucosal and epithelial barrier systems. Collectively, these deficits contribute to the loss of immune tolerance, persistent inflammatory signaling, and increased susceptibility to both environmental and endogenous triggers.

Commensal microbes, latent viral reservoirs, translocated microbial products such as lipopolysaccharide, and metabolic byproducts may then act as secondary drivers of immune activation. In this setting, the microbiome itself becomes a source of biotoxic burden, not as a primary cause, but as a consequence of impaired innate immune regulation. The persistence of both exogenous and endogenous stimuli reinforces a chronic inflammatory state that is no longer dependent on the initial exposure.

A central downstream consequence of IID is the progressive loss of barrier integrity. Barrier function represents a coordinated, system-wide network that includes the gastrointestinal epithelium, respiratory mucosa, blood–brain barrier, cutaneous (integumentary) barrier, urogenital tract, lymphatic system, and cellular membranes. Innate immune signaling is essential for maintaining these barriers through regulation of tight junction proteins, antimicrobial peptide production, immune tolerance, and tissue repair.

Chronic activation of pattern recognition receptors, including TLR4 and NLRP3, disrupts these regulatory processes, leading to degradation of tight junction proteins such as ZO-1 and claudin-1, reduced mucosal immune tolerance, and impaired epithelial signaling. As barrier integrity declines, environmental toxins, microbial products, and opportunistic organisms gain increased access to systemic circulation and underlying tissues, further amplifying immune activation.

Within this framework, dysbiosis is not the initiating event, but a downstream consequence of innate immune dysfunction and barrier failure. The inability to regulate microbial populations and maintain mucosal immunity allows for expansion of pathobionts, increased production of endotoxins and secondary metabolites, and sustained activation of innate immune pathways.

This model provides a mechanistic basis for the multisystem nature of Chronic Inflammatory Response Syndrome and its overlap with Inflammatory Bowel Disease. In genetically susceptible individuals, IBD may be best understood as a gut-predominant manifestation of systemic innate immune dysregulation, where loss of barrier integrity, microbial translocation, and persistent immune activation converge to drive chronic intestinal inflammation.

Limitations of Symptom-Focused Care

Current pharmacologic and biologic strategies for Inflammatory Bowel Disease are largely directed toward suppression of downstream inflammatory pathways rather than correction of the upstream immune dysfunction that drives them. While these approaches may provide short-term symptomatic relief, they do not restore immune regulation and therefore demonstrate limited long-term efficacy, particularly in the context of innate immune dysregulation.

Across therapeutic classes, clinical remission rates remain modest, with induction typically achieved in 15–45% of patients and maintenance remission in approximately 30–50%. Steroid-free remission rates are consistently lower, often falling below 30% at one year. These outcomes underscore the limitations of therapies that target inflammatory mediators without addressing upstream drivers of disease.

Conventional therapies reflect these limitations. Mesalamine demonstrates minimal efficacy beyond mild disease. Corticosteroids may induce short-term remission but fail to maintain it and are associated with significant adverse effects. Biologic agents, including TNF-α inhibitors, anti-integrin therapies, and IL-23 inhibitors, improve outcomes in subsets of patients but do not achieve durable remission in the majority and are associated with increased risks, including infection, immunogenicity, and malignancy.

Mechanistically, these approaches do not address the underlying drivers of immune dysregulation. Broad immunosuppression may exacerbate microbial persistence in individuals with impaired innate immune function, particularly in the presence of dysbiosis or elevated pathogen burden. Targeted therapies, including JAK inhibitors, similarly fail to account for environmental and metabolic influences on immune signaling pathways. For example, mycotoxins such as Deoxynivalenol (DON) can directly alter JAK2 signaling and downstream immune transcription, potentially limiting the effectiveness of pharmacologic inhibition.

Other emerging interventions remain similarly limited. Stem cell therapies offer transient symptomatic improvement but do not reliably restore immune regulatory networks. Fecal microbiota transplantation may modulate microbial composition but does not correct the underlying immune dysfunction that permits dysbiosis to persist. Gene-targeted approaches focusing on loci such as NOD2, ETS2, or FUT2 fail to account for environmental and epigenetic drivers of disease.

Despite decades of therapeutic advancement, unmedicated, durable remission has not been achieved through pharmacologic approaches alone. In the absence of strategies that address both persistent environmental and endogenous triggers and the underlying failure of immune regulation, relapse remains common.

Collectively, these findings suggest that symptom-focused approaches are insufficient to achieve sustained remission in conditions driven by innate immune dysregulation, and that restoration of immune regulation represents a necessary therapeutic target.

Restoring Innate Immunity: CIRS Protocol + Site-Specific Immunomodulation

The CIRS treatment protocol is designed to reduce biotoxin burden and mitigate downstream inflammatory signaling through a combination of environmental remediation and targeted interventions. Core components include removal of ongoing environmental exposures, high-dose omega-3 fatty acids (EPA/DHA), and bile acid sequestration with agents such as cholestyramine to support elimination of circulating biotoxins.

While these interventions address ongoing exposure and toxin burden, restoration of innate immune function remains a critical therapeutic objective. QuBiologic’s Site-Specific Immunomodulation (SSI), exemplified by QBECO, represents an emerging approach aimed at retraining innate immune responses rather than suppressing downstream inflammation.

QBECO SSI is composed of sterile, heat-killed Escherichia coli and is administered subcutaneously over several weeks. This therapy induces localized chemokine signaling at the ileocolonic mucosa, promoting targeted recruitment of monocytes and reprogramming of innate immune transcriptional responses. Reported effects include modulation of immune-inflammatory gene expression, restoration of natural killer (NK) cell activity, enhanced antigen presentation, and improved immune surveillance.

Through these mechanisms, QBECO facilitates improved coordination between innate and adaptive immune responses and enhances the host’s capacity to recognize and clear persistent biotoxins, infections, and microbial products. Notably, QBECO is formulated without endotoxins, antigenic proteins, or adjuvants and is delivered in preservative-free saline, contributing to a safe and tolerable profile.

Early clinical studies in moderate to severe Inflammatory Bowel Disease have reported medication-free remission rates of approximately 65–76% following QBECO therapy. While these findings require further validation in larger controlled trials, they contrast with the more limited remission rates observed with conventional pharmacologic approaches.

Given the complementary mechanisms of action, combining innate immune retraining with the CIRS Treatment Protocol may offer synergistic benefit by addressing both ongoing biotoxin exposure and the underlying failure of immune regulation.

Beyond gastrointestinal disease, QBECO has demonstrated activity in other conditions associated with innate immune dysfunction. In oncology settings, restoration of NK cell cytotoxicity and improved tumor antigen recognition have been associated with enhanced immune-mediated clearance of malignant cells in early-stage investigations. Preclinical models have also demonstrated effects in metabolic dysfunction–associated liver disease, where reprogramming of hepatic innate immune cells, including Kupffer cells and monocyte-derived macrophages, has been associated with reduced inflammation, decreased steatosis, and attenuation of fibrotic remodeling.

These findings support the classification of QBECO as a systemically active innate immune–restoring therapy capable of correcting immune dysfunction across multiple systems. In the context of biotoxin-driven disease, this approach offers a mechanism to restore immune regulation, improve barrier integrity, and interrupt the self-sustaining cycle of inflammation without introducing additional antigenic or adjuvant-related burden.

Discussion

This paper proposes that in genetically and epigenetically susceptible individuals, particularly carriers of HLA-DR and DQ haplotypes 4-3-53 and 11-3-52B, Inflammatory Bowel Disease is more accurately understood as a gut-predominant manifestation of innate immune dysregulation rather than a gut-limited autoimmune condition. The resulting immune disturbances produce downstream features consistent with Chronic Inflammatory Response Syndrome and are sustained by both exogenous and endogenous biotoxin exposures.

This framework provides a unifying explanation for key features of IBD, including loss of barrier integrity, microbial dysbiosis, epithelial hypoxia, and disruption of mucosal immune function. Within this model, these findings are not independent processes but downstream consequences of impaired immune regulation. This perspective shifts the focus of disease pathogenesis from downstream inflammatory signaling to upstream immune injury.

Although this model is strongly supported by mechanistic and clinical data, the current evidence base remains largely observational. There is a pressing need for well-designed controlled trials evaluating interventions that address both biotoxin burden and restoration of innate immune function. Future studies should prioritize stratification based on HLA genotype, biotoxin exposure history, and objective markers of innate immune dysfunction to better identify patient subgroups most likely to benefit from targeted interventions and to monitor therapeutic response.

Conclusion

In genetically susceptible individuals, Inflammatory Bowel Disease may be best understood as a gut-dominant manifestation of innate immune dysregulation, with downstream inflammatory features consistent with Chronic Inflammatory Response Syndrome.

Environmental biotoxins, including mold-derived mycotoxins, bacterial endotoxins, vector-borne pathogens, and immunogenic exposures, including vaccine-derived antigens and adjuvants, activate innate immune signaling pathways including NLRP3 inflammasome activation and Toll-like receptor pathways. This activation promotes epigenetic reprogramming of monocytes and dendritic cells, resulting in persistent alterations in immune function.

The resulting innate immune dysfunction disrupts neuroimmune signaling, impairs immune tolerance, reduces mucosal immune competence, and compromises barrier integrity. These upstream disturbances give rise to secondary phenomena including dysbiosis, microbial translocation and localized gastrointestinal inflammation.

The limitations of symptom-suppressive strategies are reflected in persistently low long-term remission rates. In contrast, approaches that combine reduction of biotoxin burden with restoration of innate immune function have shown potential to improve outcomes, including the achievement of medication-free remission.

This shift toward a model of biotoxin-triggered immune injury has important clinical and research implications. It supports the need for improved identification of susceptible individuals, early intervention strategies, and targeted therapies aimed at restoring immune regulation. It also underscores the importance of environmental and public health considerations in disease prevention.

IBD should not be viewed solely as a disorder of the gastrointestinal tract, but as a manifestation of systemic immune dysfunction. In susceptible individuals, progressive loss of immune regulation leads to impaired surveillance, loss of tolerance, and sustained inflammatory signaling. The gastrointestinal tract, with its dense immune network and constant exposure to environmental and microbial stimuli, becomes a primary site of disease expression, although the underlying dysfunction is systemic.

Durable, unmedicated remission in Inflammatory Bowel Disease will likely require more than suppression of symptoms or inflammatory signaling. It requires removal of persistent biotoxin exposures alongside restoration of innate immune function to reestablish immune regulation, tolerance, and resilience. This framework supports approaches that extend beyond symptom management toward interventions that address the underlying immunological and environmental drivers of disease.

Acknowledgments

We thank Dr R. Shoemaker for foundational CIRS research, and QuBiologics for sharing unpublished SSI data.

Funding

No external funding was received.

Conflicts of Interest

None.

References

Dooley M, Vukelic A, Jim L. Chronic inflammatory response syndrome: a review of the evidence of clinical efficacy of treatment. PMID: 39649915; PMCID: PMC11623837.
Shoemaker RC, Heyman A. Chronic Inflammatory Response Syndrome. Toxins. 2020;12(10):680. PMID: 32922723.
Exley C, Aluminium in the human brain. Front Neurol. 2019;10:1143. PMID: 31798454.
Li J et al. NLRP3 inflammasome activation by aluminum adjuvants promotes innate immune memory. Nat Commun. 2021;12:2787. PMID: 34163256.
Vojdani A, Kharrazian D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to autoimmune diseases. Clin Immunol. 2020;217:108480. PMID: 30204106.
Gherardi RK et al. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminum hydroxide in muscle and lymph nodes. Brain. 2021;144(3):721–735. PMID: 28752221.
Tay MZ et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363–374. PMID: 32346093.
Krause PR et al. Immunological considerations for COVID-19 vaccine strategies. Science. 2020;370(6518):18–23. PMID: 36385415.
Liu M, Yu J, He Y, Zhang Y, Wang Y, Yin H.
Deoxynivalenol hijacks the pathway of Janus kinase 2/signal transducers and activators of transcription 3 (JAK2/STAT-3) to drive caspase-3-mediated apoptosis in intestinal porcine epithelial cells 2023;443:130242. PMID: 36565876
Ghosh S et al. Mycotoxins impair tight junctions and increase intestinal permeability. Toxins. 2017;9(11):345. PMID: 28064169.
Netea MG et al. Trained immunity: A program of innate immune memory in health and disease. Science. 2016;352(6284):aaf1098. PMID: 28166263.
Fasano A. Zonulin, regulation of tight junctions, and autoimmune diseases. Ann N Y Acad Sci. 2012;1258:25–33. PMID: 21248165.
Krishnan SM et al. Innate immune training via QBECO restores epithelial immune tone and tissue regeneration. J Crohns Colitis. 2024;18:555–566. PMID: 37945510.
Zhang C et al. Immune dysfunction in chronic mold illness. Front Immunol. 2019;10:2862. PMID: 31798454.
Peterson LW, Artis D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol. 2014;14:141–153. PMID: 24566914.
Qu Biologics. QBECO SSI for Crohn’s Disease achieves remission in drug-resistant IBD patients. J Crohns Colitis. 2024;18:555–566. PMID: 37945510.
Ando M et al. Immunological studies of chronic hypersensitivity pneumonitis induced by Saccharopolyspora rectivirgula. J Allergy Clin Immunol. 1991;88(6):952–964. PMID: 1743781.
Netea MG et al. Trained immunity: A program of innate immune memory in health and disease. Science. 2016;352(6284):aaf1098. PMID: 28166263.
Michel O et al. Inhaled endotoxin induces bronchial hyperresponsiveness in healthy subjects. Am J Respir Crit Care Med. 1997;156(2 Pt 1):331–336. PMID: 9279206.
Watkins SM et al. Exposure to marine algal toxins: a review of seafood poisoning syndromes and associated toxins. Toxicon. 2008;56(2):123–134. PMID: 24336052.
Yasumoto T et al. Toxicological evaluation of marine toxins. Toxicon. 2000;39(1):101–108. PMID: 23098569.
Pan Q, Tarrant TK, Krishnan SM, et al. Immune retraining with QBECO resolves chronic inflammation in a mouse model of fatty liver disease. Hepatology Communications. 2024. PMID: 38813572.
Krishnan SM et al. Innate immune training via QBECO restores epithelial immune tone and tissue regeneration. J Crohns Colitis. 2024;18:555–566. PMID: 37945510.
Lutzky VP, Quirt I, et al. Immunotherapy with microbial-based QBECO leads to tumor regression in refractory cancer patients. OncoImmunology. 2023. PMID: 36722835.
Krishnan L, Sadarangani M, Pan Q, et al. Local immune activation drives tumor regression via site-specific innate training. Sci Transl Med. 2019;11(528):eaav0947. PMID: 30626571.